Phase II data for Celgene's investigational oral ged-0301 for patients with active Crohn's disease published

Celgene Corporation has announced that results from a double-blind, placebo-controlled, multicenter phase II trial of three doses of GED-0301 (mongersen) in patients with active Crohn's...